One can refer to post above by Dane Swan:
"FY21 product development costs in Cash flow Q4 YTD $321k, produced $3.983m revenue
Fy22 product development costs in Cash flow Q4 YTD at $910k, annual report $1.204m produced $9m in revenue
FY23 product development costs in cash flow Q2 YTD, $1.153, would estimate $8-$9m, split over Q2 & Q3, as $210k these costs are in Q1."
Product development costs increasing as business grows revenue but actual cash receipts are driving negative OPCF and declining bank balance - this is the financial reality requiring management action rather than omission.
Should have been addressed a long time ago and managed (with earlier preemptive raise?).
Now business has no wriggle room...if cash receipts don't dramatically improve...cost of denial will be sub 10c raise...
One can refer to post above by Dane Swan:"FY21 product...
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 3DP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.4¢ |
Change
0.008(12.1%) |
Mkt cap ! $59.57M | |||
| Open | High | Low | Value | Volume |
| 7.1¢ | 7.5¢ | 6.7¢ | $318.7K | 4.379M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 523319 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 1540687 | 7 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| 3DP (ASX) Chart |